Cara Therapeutics Inc (NAS:CARA)
$ 0.2908 -0.0132 (-4.34%) Market Cap: 15.95 Mil Enterprise Value: -21.94 Mil PE Ratio: 0 PB Ratio: 29.08 GF Score: 33/100

Cara Therapeutics, Inc. - Special Call Transcript

Dec 03, 2019 / 01:30PM GMT
Release Date Price: $16.94 (-34.54%)
Operator

Good morning, and welcome to Cara Therapeutics Oral KORSUVA CKD-associated Pruritus Phase II Top Line Data Conference Call. (Operator Instructions) Please be advised that this call is being recorded at Cara's request.

I would now like to turn the call over to the Cara team. Please proceed.

Jane Urheim
Stern Investor Relations, Inc. - IR Executive

Good morning. This is Jane with Stern Investor Relations, and welcome to Cara Therapeutics Oral KORSUVA CKD-associated Pruritus Phase II Top Line Data Conference Call. The news release became available at 7:00 a.m. Eastern Time today and can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today's call on the Investors section of the website.

I'll now turn the call over to Dr. Derek Chalmers, Cara President and CEO.

Derek T. Chalmers
Cara Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Jane. Good morning

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot